52.89
price down icon1.65%   -0.89
after-market Handel nachbörslich: 52.89
loading

Agios Pharmaceuticals Inc Aktie (AGIO) Neueste Nachrichten

pulisher
Nov 17, 2024

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Update - MarketBeat

Nov 17, 2024
pulisher
Nov 16, 2024

Brokerages Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Price Target at $52.33 - MarketBeat

Nov 16, 2024
pulisher
Nov 14, 2024

ARMISTICE CAPITAL, LLC Expands Portfolio with Agios Pharmaceuticals Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 12, 2024

Agios Pharmaceuticals director sells shares worth $1.12 million By Investing.com - Investing.com Canada

Nov 12, 2024
pulisher
Nov 12, 2024

Agios Pharmaceuticals chief legal officer sells $1.14 million in stock - Investing.com

Nov 12, 2024
pulisher
Nov 09, 2024

StockNews.com Upgrades Agios Pharmaceuticals (NASDAQ:AGIO) to Hold - MarketBeat

Nov 09, 2024
pulisher
Nov 08, 2024

Agios stock soars to 52-week high, reaching $53.28 By Investing.com - Investing.com Canada

Nov 08, 2024
pulisher
Nov 07, 2024

Agios stock soars to 52-week high, reaching $53.28 - Investing.com

Nov 07, 2024
pulisher
Nov 07, 2024

Agios Pharmaceuticals (NASDAQ:AGIO) Is Posting Healthy Earnings, But It Is Not All Good News - Yahoo Finance

Nov 07, 2024
pulisher
Nov 05, 2024

Agios Pharmaceuticals' SWOT analysis: promising pipeline, cash boost fuel stock outlook - Investing.com India

Nov 05, 2024
pulisher
Nov 05, 2024

Mirae Asset Global Investments Co. Ltd. Acquires 363 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World

Nov 05, 2024
pulisher
Nov 05, 2024

Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition - The Manila Times

Nov 05, 2024
pulisher
Nov 05, 2024

Agios to Unveil Critical Phase 3 Data for Blood Disorder Drugs at ASH 2024 | AGIO Stock News - StockTitan

Nov 05, 2024
pulisher
Nov 04, 2024

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Sold by Assenagon Asset Management S.A. - MarketBeat

Nov 04, 2024
pulisher
Nov 03, 2024

Agios Pharmaceuticals (NASDAQ:AGIO) Rating Lowered to “Sell” at StockNews.com - Defense World

Nov 03, 2024
pulisher
Nov 02, 2024

Agios Pharmaceuticals (NASDAQ:AGIO) Downgraded to "Sell" Rating by StockNews.com - MarketBeat

Nov 02, 2024
pulisher
Nov 01, 2024

Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) - Benzinga

Nov 01, 2024
pulisher
Nov 01, 2024

Agios Pharmaceuticals (NASDAQ:AGIO) Given "Outperform" Rating at Royal Bank of Canada - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Agios Pharmaceuticals (NASDAQ:AGIO) Given New $53.00 Price Target at Scotiabank - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Agios shares hold Strong Buy rating, $51 target from Raymond James - Investing.com Australia

Nov 01, 2024
pulisher
Nov 01, 2024

Earnings call: Agios Pharmaceuticals reports Q3 2024 financials, plans launches - Investing.com Australia

Nov 01, 2024
pulisher
Nov 01, 2024

Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Agios Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 01, 2024
pulisher
Nov 01, 2024

Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings Call Highlights: Strong Cash Position and Strategic Advancements - GuruFocus.com

Nov 01, 2024
pulisher
Nov 01, 2024

Agios Pharmaceuticals: Q3 Earnings Snapshot - The Advocate

Nov 01, 2024
pulisher
Nov 01, 2024

Agios Pharmaceuticals Reports Robust Q3 2024 Results - TipRanks

Nov 01, 2024
pulisher
Oct 31, 2024

Agios Pharmaceuticals (AGIO) Misses Q3 Earnings and Revenue Estimates - MSN

Oct 31, 2024
pulisher
Oct 31, 2024

Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings: EPS Surpasses Estimates, Revenue at $9.0 Million - GuruFocus.com

Oct 31, 2024
pulisher
Oct 31, 2024

Agios Reports Business Highlights and Third Quarter 2024 Financial Results - The Manila Times

Oct 31, 2024
pulisher
Oct 30, 2024

Earnings Preview: Agios Pharmaceuticals - Benzinga

Oct 30, 2024
pulisher
Oct 30, 2024

Leerink Partnrs Issues Optimistic Estimate for AGIO Earnings - MarketBeat

Oct 30, 2024
pulisher
Oct 25, 2024

Analysts Are Optimistic We'll See A Profit From Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Simply Wall St

Oct 25, 2024
pulisher
Oct 25, 2024

Equities Analysts Set Expectations for AGIO Q3 Earnings - MarketBeat

Oct 25, 2024
pulisher
Oct 24, 2024

Agios Pharmaceuticals' SWOT analysis: stock outlook amid SCD market shifts By Investing.com - Investing.com Australia

Oct 24, 2024
pulisher
Oct 24, 2024

Agios Pharmaceuticals (AGIO) Set to Announce Quarterly Earnings on Thursday - MarketBeat

Oct 24, 2024
pulisher
Oct 24, 2024

Agios Pharmaceuticals' SWOT analysis: stock outlook amid SCD market shifts - Investing.com India

Oct 24, 2024
pulisher
Oct 24, 2024

Servier vorasidenib PDUFA near, Agios wins in thalassemia - BioWorld Online

Oct 24, 2024
pulisher
Oct 24, 2024

Agios completes enrollment for sickle cell disease trial By Investing.com - Investing.com Canada

Oct 24, 2024
pulisher
Oct 23, 2024

Agios completes enrollment for sickle cell disease trial - Investing.com

Oct 23, 2024
pulisher
Oct 23, 2024

Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease - The Manila Times

Oct 23, 2024
pulisher
Oct 22, 2024

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Oct 22, 2024
pulisher
Oct 19, 2024

(AGIO) Investment Report - Stock Traders Daily

Oct 19, 2024
pulisher
Oct 17, 2024

Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024 - StockTitan

Oct 17, 2024
$18.98
price up icon 3.66%
$76.97
price up icon 1.45%
$39.51
price up icon 7.22%
$359.21
price down icon 1.11%
$187.69
price down icon 0.81%
$101.87
price up icon 2.16%
Kapitalisierung:     |  Volumen (24h):